Benefits of Early Everolimus-Based Quadruple Immunosuppression Early After Lung Transplantation - Results of 4EVERLUNG, a Prospective Randomized Multicenter Trial

Lowering calcineurin inhibitor (CNI) exposure to avoid toxicity is desirable after solid organ transplantation although the risk of organ rejection is of concern after lung transplantation (LTx). The 4Everlung trial was designed to evaluate the benefit of early everolimus (EVR)-based quadruple low immunosuppressive (IS) regimen on kidney function (RF) after LTx

Source: The Journal of Heart and Lung Transplantation - March 31, 2018 Category: Transplant Surgery Authors: J. Gottlieb, C. Neurohr, J. M üller-Quernheim, H. Wirtz, B. Sill, H. Wilkens, V. Besa, C. Knosalla, M. Junge, C. Capusan, M. Strüber Source Type: research